Shots:

• The EU has approved Fasenra (benralizumab) as an add-on therapy for treating r/r eosinophilic granulomatosis with polyangiitis (EGPA) in adults
• The approval was based on a P-III (MANDARA) trial assessing the safety & efficacy of Fasenra (single 30mg, SC, Q4W) vs mepolizumab (separate 100mg, SC, Q4W) for treating adults (n=140) with r/r EGPA, in ratio 1:1
• The study demonstrated remission in 60% of them (comparable to mepolizumab) and 41% vs 26% fully stopped oral corticosteroids (OCS), with safety & tolerability that aligned with the previous profiles of the drugs. Data was published in the NEJM

Ref: AstraZeneca | Image: AstraZeneca

Related News:- Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from AstraZeneca

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com